



## Predicting Success of Phase III Trials in Oncology

Stephan J Hegge, Markus Erik Thunecke, Matthias Krings, Leonard Ruedin, Jan Saputra Mueller, Paul von Buenau

doi: <https://doi.org/10.1101/2020.12.15.20248240>

**This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.**

[Abstract](#)[Info/History](#)[Metrics](#)[Preview PDF](#)

### Abstract

We developed a model predicting the probability of success (PoS) for single planned or ongoing PhIII trials based on information available at trial initiation. Such a model is highly relevant for study sponsors to capture risk and opportunity on a trial to trial basis through trial optimization, and for investors to select drugs whose trial design match their investment strategy. Objectives: To predict the outcome of planned or ongoing PhIII trials in oncology, given publicly available prior information Design, Setting, Participants: Predictive modeling using publicly available data for 360 completed PhIII and 1240 PhII studies initiated between 2003 and 2012. Success and failure of PhIII studies were modeled using Bayesian logistic regression model. Main Outcome Measures: Predicted PoS of individual PhIII trials based on a Bayesian model calibrated on publicly available data translated into 16 composite scores. Those scores cover aspects such as trial design, indication, number of patients, phase II (PhII) study outcomes, experience of sponsor at time of trial initiation, and others. Results: The model allows to calculate the PoS distribution, including credible intervals, for a PhIII trial in oncology. The predictive performance was determined using an area under the receiver operator curve (AUROC), resulting in an overall performance of 73%oPP (mean AUROC). We identified two key factors contributing to the predictive performance of the model: quality and strength of PhII data and experience of the sponsor at the time of study initiation. Conclusion and Relevance: We describe the generation

and application of a statistical model predicting the PoS for individual PhIII trials in oncological indications with unprecedented predictive performance. Compared to other approaches, this is the first study generating a fully transparent model resulting in trial specific PoS distributions. Moreover, we have shown that qualitative concepts such as PhII knowledge or sponsor R&D strength can be captured in quantitative scores and that these scores have a high predictive power.

### **Competing Interest Statement**

Conflict of Interest: No conflicts of interest are declared for JSM, PvB, MK. SH, LR and MT have personal investments in several biotechnology companies. SH is Senior Director of Corporate Strategy at HotSpot Therapeutics Inc. and general manager of Hegge Holding UG. JSM is co-founder of AskBy GmbH.

### **Funding Statement**

No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this paper).

### **Author Declarations**

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No Institutional Review Board was required for data presented in this document.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

## Copyright

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

## medRxiv Comment Policy

Comments are moderated for offensive or irrelevant content (can take ~24 hours). Duplicated submission is unnecessary.

Please read our Comment Policy before commenting.



0 Comments [medRxiv](#) [Disqus' Privacy Policy](#)

[1 Login](#)

[Recommend](#) [Tweet](#) [Share](#)

[Sort by Newest](#)



Start the discussion...

LOG IN WITH

OR SIGN UP WITH DISQUS [?](#)

Name

Be the first to comment.

[Subscribe](#) [Add Disqus to your site](#) [Add DisqusAdd](#) [Do Not Sell My Data](#)

[^ Back to top](#)

[Previous](#)

[Next](#)

Posted December 16, 2020.

[Download PDF](#)

[Author Declarations](#)

[Supplementary Material](#)

[Data/Code](#)

[Email](#)

[Share](#)

[Citation Tools](#)

## COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

### Subject Area

Oncology 

### Subject Areas

#### All Articles

Addiction Medicine  
Allergy and Immunology  
Anesthesia  
Cardiovascular Medicine  
Dentistry and Oral Medicine  
Dermatology  
Emergency Medicine  
Endocrinology (including Diabetes Mellitus and Metabolic Disease)  
Epidemiology  
Forensic Medicine  
Gastroenterology  
Genetic and Genomic Medicine  
Geriatric Medicine  
Health Economics  
Health Informatics  
Health Policy  
Health Systems and Quality Improvement  
Hematology  
HIV/AIDS  
Infectious Diseases (except HIV/AIDS)  
Intensive Care and Critical Care Medicine  
Medical Education  
Medical Ethics  
Nephrology  
Neurology  
Nursing  
Nutrition  
Obstetrics and Gynecology

Occupational and Environmental Health  
Oncology  
Ophthalmology  
Orthopedics  
Otolaryngology  
Pain Medicine  
Palliative Medicine  
Pathology  
Pediatrics  
Pharmacology and Therapeutics  
Primary Care Research  
Psychiatry and Clinical Psychology  
Public and Global Health  
Radiology and Imaging  
Rehabilitation Medicine and Physical Therapy  
Respiratory Medicine  
Rheumatology  
Sexual and Reproductive Health  
Sports Medicine  
Surgery  
Toxicology  
Transplantation  
Urology

